Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Week In Review: FutureGen Sells mAb For IBD To AbbVie In $1.7 Billion Deal By: TalkMarkets June 22, 2024 at 13:40 PM EDT FutureGen Biopharm out-licensed global rights for its next-gen TL1A antibody to AbbVie in a $1.7 billion agreement. Also, MabCare Therapeutics out-licensed global rights for its ADC targeting protein-tyrosine kinase 7 candidate to Day One Biopharma. Read More >> Related Stocks: AbbVie Day One Biopharmaceuticals Inc Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Week In Review: FutureGen Sells mAb For IBD To AbbVie In $1.7 Billion Deal By: TalkMarkets June 22, 2024 at 13:40 PM EDT FutureGen Biopharm out-licensed global rights for its next-gen TL1A antibody to AbbVie in a $1.7 billion agreement. Also, MabCare Therapeutics out-licensed global rights for its ADC targeting protein-tyrosine kinase 7 candidate to Day One Biopharma. Read More >> Related Stocks: AbbVie Day One Biopharmaceuticals Inc